Cuba studied 18,403 samples for COVID-19, resulting in 906 positive ones. The country accumulates 1,904,926 samples taken and 27,592 positive.

The second phase of the clinical trial of the vaccine candidate CIGB 66 (Abdala), one of the four nationally produced against COVID-19, begins this Monday at the Saturnino Lora provincial hospital in Santiago de Cuba.

Conditions are created to try to start the trial with the vaccine candidates Soberana 01 and Soberana 02 in children and teenagers by the end of February, informed Doctor of Science Vicente Vérez Bencomo, general director of the Finlay Vaccine Institute (IFV).

Cuba studied 13,903 samples for COVID-19, resulting in 659 positive ones. The country accumulates 1, 851,950 samples taken and 24,764 positive.

The anti-COVID-19 vaccine candidate CIGB 66, known as Abdala, is advancing to the second phase of the clinical trial, scheduled to begin on February 1 at the Saturnino Lora provincial hospital in Santiago de Cuba.

Cuba reported today 666 new cases of the SARS-CoV-2 and four deaths from the infectious disease, for a total of 24,105 positive cases and 208 deceases.

Cuba reported 825 confirmed COVID 19 cases Wednesday, the highest figure for a single day since the pandemic’s onset here in March 2020.

The first virtual conference on the management and control of leprosy will begin its sessions today in Havana with the pre-National Conference course on this disease, where lectures will be given by renowned professors in the specialty of dermatology.

HAVANA, Cuba, Jan 27 (ACN) Cuban vaccine candidates Soberana 01 and 02, developed by the Finlay Vaccine Institute (IFV), are advancing their clinical trials at an accelerated pace in view of the global emergency decreed by the COVID-19 pandemic.

Among the main modifications made to the Cuban protocol for the clinical management of patients with COVID-19 is to treat patients classified as high-risk sufficiently in advance and to do so in a differentiated manner by means of intensive surveillance.

Cuba reported today 786 new SARS-CoV-2 cases, an all-time high for one day since the beginning of the pandemic in the country last March.

The Cuban drug Itolizumab, created by the Center for Molecular Immunology, was recently used as an anti-inflammatory therapy treatment for three COVID-19 positive patients, with encouraging results.

The official account of the Cuban Presidency highlights today on Twitter the favorable progress of the vaccine candidate Abdala, whose results and safety and immunogenicity levels are already proven in the country.

The Cuban ministry of foreign affairs (MINREX by its Spanish acronym) posted today on Twitter that a group of eleven doctors and four laboratorians are already in Barbados to complete the brigade of the Henry Reeve contingent that supports the work of confronting the COVID-19 pandemic in that Caribbean nation.